Fantasy Football - Footballguys Forums
This is a sample guest message. Register a free account today to become a member! Once signed in, you'll be able to participate on this site by adding your own topics and posts, as well as connect with other members through your own private inbox!
Stock Thread (14 Viewers)
- Thread starter St. Louis Bob
- Start date
SFBayDuck
Footballguy
I have shares I'm still holding that converted from the Xilinx shares I owned.....trying to decide if I just take the gains I have left now, or maybe wait a bit to see if there is buy on this dip.
The Commish
Footballguy
Not sure.....the materials that were quality at one time are now cheap aluminum. The electronics are cheap and poorly constructed as well. I had one of the very first ones that came out and would likely still have it had it not gotten stolen back in the day. I was in the market for one again a couple years ago and went to look at them and was shocked at what I found compared to what I had bought several years prior.
2Squirrels1Nut
Footballguy
I was wondering what happened. Crazy that it's going up like this.$GME stock split.
ETA
"A stock split in the form of a dividend" What?
Last edited by a moderator:
Freak Show
Footballguy
I bought a little Home Depot HD today.
Todem
Footballguy
Pure lotto ticket.Go away for a week. Then have been real busy with work and haven't been tracking stocks. I did feel super rich for a few days. These last two days were kind of jerks though. GME the only winner
Period.
Same with AMC.
2Squirrels1Nut
Footballguy
I agree and sincerely hope @David Doddscan at least play with house money with this run up. The options numbers I'm looking at predict a slow retrace well below $100. That just IMHO I'm by no means an expert. FWIW I posted they predicted this surge.
2Squirrels1Nut
Footballguy
Added 15 of these for $0.16 each.
I don't have any concrete reason for this. More of a hunch. We have come back, which is great, but so much bad news out there.
beef
Footballguy
Capella
Footballguy
2Squirrels1Nut
Footballguy
The Tellurion CEO was on Cramer last night. The last thing he said before commercial was it's a good company but small and not to be run up.
Currently up 20%
Don't know whether to
or 
Currently up 20%
Don't know whether to
or 
identikit
Footballguy
Al Czervik
Not wearing pants
2Squirrels1Nut
Footballguy
No kidding. Seemed to reverse when it was announced there are a lot more over the road truck drivers than needed.
2Squirrels1Nut
Footballguy
Go on , take the money and run
Cramer certainly deserves some criticism at times but all I could hear in my head was "pigs get slaughtered". Also @siffoinand @Todemposting "you never go broke taking a profit. I could have sold a day earlier for a $2000 gain and if I would have held just an hour longer would be worthless. Thanks guys!
Last edited by a moderator:
cosjobs
Footballguy
DIGITAL WORLD ACQUISITION CORP
$63.25
$-1.26 (-1.95%)
Bid EDGX
54.25 x 1
Ask EDGX
54.50 x 20
Volume
502,493
DWAC getting killed in pre-market.
Exclusive-Two key tech execs quit Truth Social after troubled app launch
(Reuters) - The two Southern tech entrepreneurs had the two qualities that Donald Trump's Truth Social startup needed: tech-industry expertise and a politically conservative worldview aligned with the former president, a rare combination in the liberal-leaning industry centered in San Francisco.
Josh Adams and Billy Boozer - the company's chiefs of technology and product development - joined the venture last year and quickly became central players in its bid to build a social-media empire, backed by Trump's powerful brand, to counter what many conservatives deride as "cancel culture" censorship from the left.
Less than a year later, both have resigned their senior posts at a critical juncture for the company's smartphone-app release plans, according to two sources familiar with the venture.
I'm not going to get rich off this, but I'll make at least a few thousand
$63.25
$-1.26 (-1.95%)
Bid EDGX
54.25 x 1
Ask EDGX
54.50 x 20
Volume
502,493
DWAC getting killed in pre-market.
Exclusive-Two key tech execs quit Truth Social after troubled app launch
(Reuters) - The two Southern tech entrepreneurs had the two qualities that Donald Trump's Truth Social startup needed: tech-industry expertise and a politically conservative worldview aligned with the former president, a rare combination in the liberal-leaning industry centered in San Francisco.
Josh Adams and Billy Boozer - the company's chiefs of technology and product development - joined the venture last year and quickly became central players in its bid to build a social-media empire, backed by Trump's powerful brand, to counter what many conservatives deride as "cancel culture" censorship from the left.
Less than a year later, both have resigned their senior posts at a critical juncture for the company's smartphone-app release plans, according to two sources familiar with the venture.
I'm not going to get rich off this, but I'll make at least a few thousand
cosjobs
Footballguy
I'm starting establish a position in LGVN (Longeveron) a promising Alzheimer's drug.
After a Phase one trial released last week, the stock shot up to over $16. A lot of profit-taking has lowered it to $13.20 today. I do not think Americans are afraid of any disease as much as Alzheimer's and I think this stock might be a great long-term hold and I am buying at this entry point.
From the trial:
that Lomecel-B was well tolerated in this patient population. In addition, the data provided indications supporting further exploration of Lomecel-B, particularly the therapeutic potential to slow cognitive decline and improve quality of life in patients with AD.
“We are pleased and encouraged by the publication of our study in this high-impact journal,” said Geoff Green, CEO of Longeveron. “The Lomecel-B study was funded by two competitive Part the Cloud Neuroinflammation Challenge grants awarded to Longeveron from the Alzheimer’s Association, for which we are extremely grateful.”
The article, titled “Results and Insights from a Phase 1 Clinical Trial of Lomecel-B for Alzheimer’s disease,” details the study findings on Longeveron’s lead investigational product, Lomecel-B, an allogeneic bone marrow-derived medicinal signaling cell (MSC) product, given to patients with mild Alzheimer’s disease.
“What makes this study unique is the use of a cellular therapy that may potentially target multiple pathological features of Alzheimer’s disease simultaneously,” said Dr. Mark Brody, lead author of the manuscript. “Not only did the study meet its primary endpoint of safety, but it also suggests the potential that Lomecel-B could have in treating patients with Alzheimer’s disease. We found data suggesting that Lomecel-B could have effects ranging from increasing blood vessel health to reducing inflammation, which could yield promising results.”
The double-blinded, randomized, placebo-controlled trial was conducted on thirty-three patients at four clinical sites. Each patient received a single intravenous infusion of low- or high-dose Lomecel-B, or a placebo. The findings from this study are being tested in a new larger Phase 2 study, which commenced in December 2021, and has already treated the first patient and continues to enroll others. The new trial is double-blinded, randomized, and placebo-controlled, and is designed to evaluate single versus multiple doses of Lomecel-B for mild Alzheimer’s disease.
The major findings of the Phase 1 study as reported in Alzheimer’s & Dementia are as follows:
The primary endpoint -- safety -- was met. The Lomecel-B infusion was well-tolerated, and there were no treatment-related safety concerns. Importantly, patients receiving Lomecel-B were not reported to develop a serious side-effect called amyloid-related imaging abnormalities (ARIA) as assessed by magnetic resonance imaging (MRI). Other classes of Alzheimer’s drugs being tested have been reported to cause ARIA.
Other exploratory findings included:
The Mini Mental State Exam (MMSE), used to evaluate cognitive status, showed a slower decline in the low-dose Lomecel-B group versus the placebo group.
The Quality of Life in Alzheimer Disease (QOL-AD), used to evaluate patient well-being, showed a significantly higher (better) score in the low-dose Lomecel-B group versus the placebo group at six months after the single treatment.
Brain imaging by magnetic resonance imaging (MRI) showed an increase in left hippocampus volume three months after a Lomecel-B infusion in the high-dose Lomecel-B arm versus placebo. The hippocampus is a brain region critical for memory formation, which normally undergoes rapid neuron formation known as neurogenesis. This process is damaged in Alzheimer’s disease, leading patients to have reductions in the size of their hippocampus.
After a Phase one trial released last week, the stock shot up to over $16. A lot of profit-taking has lowered it to $13.20 today. I do not think Americans are afraid of any disease as much as Alzheimer's and I think this stock might be a great long-term hold and I am buying at this entry point.
From the trial:
that Lomecel-B was well tolerated in this patient population. In addition, the data provided indications supporting further exploration of Lomecel-B, particularly the therapeutic potential to slow cognitive decline and improve quality of life in patients with AD.
“We are pleased and encouraged by the publication of our study in this high-impact journal,” said Geoff Green, CEO of Longeveron. “The Lomecel-B study was funded by two competitive Part the Cloud Neuroinflammation Challenge grants awarded to Longeveron from the Alzheimer’s Association, for which we are extremely grateful.”
The article, titled “Results and Insights from a Phase 1 Clinical Trial of Lomecel-B for Alzheimer’s disease,” details the study findings on Longeveron’s lead investigational product, Lomecel-B, an allogeneic bone marrow-derived medicinal signaling cell (MSC) product, given to patients with mild Alzheimer’s disease.
“What makes this study unique is the use of a cellular therapy that may potentially target multiple pathological features of Alzheimer’s disease simultaneously,” said Dr. Mark Brody, lead author of the manuscript. “Not only did the study meet its primary endpoint of safety, but it also suggests the potential that Lomecel-B could have in treating patients with Alzheimer’s disease. We found data suggesting that Lomecel-B could have effects ranging from increasing blood vessel health to reducing inflammation, which could yield promising results.”
The double-blinded, randomized, placebo-controlled trial was conducted on thirty-three patients at four clinical sites. Each patient received a single intravenous infusion of low- or high-dose Lomecel-B, or a placebo. The findings from this study are being tested in a new larger Phase 2 study, which commenced in December 2021, and has already treated the first patient and continues to enroll others. The new trial is double-blinded, randomized, and placebo-controlled, and is designed to evaluate single versus multiple doses of Lomecel-B for mild Alzheimer’s disease.
The major findings of the Phase 1 study as reported in Alzheimer’s & Dementia are as follows:
The primary endpoint -- safety -- was met. The Lomecel-B infusion was well-tolerated, and there were no treatment-related safety concerns. Importantly, patients receiving Lomecel-B were not reported to develop a serious side-effect called amyloid-related imaging abnormalities (ARIA) as assessed by magnetic resonance imaging (MRI). Other classes of Alzheimer’s drugs being tested have been reported to cause ARIA.
Other exploratory findings included:
The Mini Mental State Exam (MMSE), used to evaluate cognitive status, showed a slower decline in the low-dose Lomecel-B group versus the placebo group.
The Quality of Life in Alzheimer Disease (QOL-AD), used to evaluate patient well-being, showed a significantly higher (better) score in the low-dose Lomecel-B group versus the placebo group at six months after the single treatment.
Brain imaging by magnetic resonance imaging (MRI) showed an increase in left hippocampus volume three months after a Lomecel-B infusion in the high-dose Lomecel-B arm versus placebo. The hippocampus is a brain region critical for memory formation, which normally undergoes rapid neuron formation known as neurogenesis. This process is damaged in Alzheimer’s disease, leading patients to have reductions in the size of their hippocampus.
joker
Footballguy
Can't remember if the Todem Master List has been updated, but this is the last one I found from Kevzilla last year:
FDX
PM
AMT
MDU
PFE
BLMN
MGM
BLDP
QS
CAT
NFLX
KO
PEP
NKE
DE
CMI
MRK
BMY
PG
WMT
LMT
DEO
TSCO
GLPI
EBS
GIS
RTX
GCV (Convertible Bonds)
ADX (for those with much smaller amounts looking for a well managed large growth closed end fund)
I just did an FBG search for "Todem Master List" in this thread, and Kev's post was the first one to pop up. Please update the list if the above has changed, thanks!
FDX
PM
AMT
MDU
PFE
BLMN
MGM
BLDP
QS
CAT
NFLX
KO
PEP
NKE
DE
CMI
MRK
BMY
PG
WMT
LMT
DEO
TSCO
GLPI
EBS
GIS
RTX
GCV (Convertible Bonds)
ADX (for those with much smaller amounts looking for a well managed large growth closed end fund)
I just did an FBG search for "Todem Master List" in this thread, and Kev's post was the first one to pop up. Please update the list if the above has changed, thanks!
2Squirrels1Nut
Footballguy
General Malaise
Footballguy
Guessing not too many of you bought Alphamin Resources (tin producer) but they are crushing it....hard to believe this is still under a buck in the US with results like this.
GRAND BAIE, Mauritius, April 04, 2022 (GLOBE NEWSWIRE) -- Alphamin Resources Corp. (AFM:TSXV, APH:JSE AltX)( “Alphamin” or the “Company”), a producer of 4% of the world’s mined tin1 from its high grade operation in the Democratic Republic of Congo, is pleased to provide the following operational update for the quarter ended March 2022:
Record Q1 EBITDA guidance of US$98m, up 32% from prior quarter actual
Contained tin sold up 9% from the prior quarter to 3,336 tonnes
Record plant recovery of 78% achieved (previous quarter: 75%)
Net cash position increases to US$129.5m, after a US$30m dividend payment
GRAND BAIE, Mauritius, April 04, 2022 (GLOBE NEWSWIRE) -- Alphamin Resources Corp. (AFM:TSXV, APH:JSE AltX)( “Alphamin” or the “Company”), a producer of 4% of the world’s mined tin1 from its high grade operation in the Democratic Republic of Congo, is pleased to provide the following operational update for the quarter ended March 2022:
Record Q1 EBITDA guidance of US$98m, up 32% from prior quarter actual
Contained tin sold up 9% from the prior quarter to 3,336 tonnes
Record plant recovery of 78% achieved (previous quarter: 75%)
Net cash position increases to US$129.5m, after a US$30m dividend payment
Gopher State
Footballguy
April is off to a good start, and it is usually the best month of the year for stocks. That being said I hope to take some profits this month starting with FB, paid $186.00, nice run up to this point. I have some other tech/oil stocks to trim. I think cash will come in handy during the second half of this year.
I know I mostly lurk here, but cell therapy is my area of expertise so I wanted to just give my perspective. MSCs have been around for a while now, and they are most certainly safe, and they are bioactive in a variety of diseases. I worked on a very similar product 10-15 years ago and we had active INDs in diseases from foot ulcers to stroke. So far, MSCs have not really been able to get over the efficacy hurdle in Phase 2/3 trials. I know nothing about this company other than just looking at their website, but they seem casting a wide net on the diseases they are looking at. Not saying it won't work, and a well designed trial goes a long way, but the history of MSCs would make me tread lightly. IMO they are still a drug looking for a disease, someone will find it but so far its been mostly anecdotal impacts.
identikit
Footballguy
General Malaise
Footballguy
Cannot believe this stock isn't higher. I have to think it gets gobbled up by a bigger resource name.
Probably get another dividend payment soon too.
2Squirrels1Nut
Footballguy
Todem
Footballguy
Missing quite a few in addition to the above:
AMZN
GOOGL
FB
JPM
LYB
DOW
O
SBUX (New addition)
AEP
PEO
DIS
CSCO
QCOM (New addition)
RBLX
UL
TGT
SHOP
NVDA
CRM
EBS was removed
QS and BLDP are super high risk names FYI
identikit
Footballguy
2Squirrels1Nut
Footballguy
2Squirrels1Nut
Footballguy
Todem
Footballguy
Selling covered calls on it all the time and if ai get called out so be it.
$50 strike going out 3 months at a time
Todem
Footballguy
Longterm hold till it gets that big pop….because one day it will.
Hydrogen cell is going to be a huge reality in commercial and public transportation.
The Man With No Name
Footballguy
Anyone have SBOW? Bought on 03/01 and am up 31%.
Up over 300% the past year. Just looking for thoughts on it from someone that owns it.
(Oil and Gas company)
Up over 300% the past year. Just looking for thoughts on it from someone that owns it.
(Oil and Gas company)
Last edited by a moderator:
2Squirrels1Nut
Footballguy
Looking to invest in the upcoming (my opinion) housing market collapse. I found DRV but not sure it's the right vehicle for my goal.
Thoughts anyone? TIA
Thoughts anyone? TIA
2Squirrels1Nut
Footballguy
SFBayDuck
Footballguy
Thesis? My take is that it would seem demographics (boomers still in their homes while millennials are ready to buy) and historically low new housing building rates the past few years would prevent a collapse. There is just still too much demand and too little supply. I do see the ridiculous price increases falling back towards historical norms going forward as rates go up and the frothiness subsides. But I'm always interested in other opinions.
2Squirrels1Nut
Footballguy
I don't think we are there yet but will be soon enough.
This expresses my opinion better than I could.
Link
Last edited by a moderator:
fruity pebbles
Footballguy
The Man With No Name
Footballguy
SBFM - from $2.26 close on Monday to $5.61 close on Tuseday. +148.23%, and it got up to $6.76 :
Oncology and antiviral drugs focused Sunshine Biopharma Inc (NASDAQ: SBFM) has said that two of its newly designed mRNA molecules can effectively destroy cancer cells grown in culture.
What Happened: The cytotoxicity tests were performed on various cancer cells, including multidrug-resistant breast cancer cells, ovarian adenocarcinoma cells, and pancreatic cancer cells.
Oncology and antiviral drugs focused Sunshine Biopharma Inc (NASDAQ: SBFM) has said that two of its newly designed mRNA molecules can effectively destroy cancer cells grown in culture.
What Happened: The cytotoxicity tests were performed on various cancer cells, including multidrug-resistant breast cancer cells, ovarian adenocarcinoma cells, and pancreatic cancer cells.
JB Breakfast Club
Footballguy
Looking uuuuuuugly again today
2Squirrels1Nut said:
From that article...
"So far, we’ve yet to see inventory post a meaningful upward bounce. Until that happens, industry insiders say, we won’t see any significant cooling in the housing market."
What's going to drive inventory?
1. We are just getting back to typically recession level of housing starts. https://ipropertymanagement.com/research/housing-starts
2. Work from home has reduced forced relocation activity.
3. Old people want to die neglecting their homes, not die neglected in an old folks home.
4. Even with Zillow dropping of the map, Wall Street is still aggressively buying.
I expect a soft landing and not a crash unless those parameters change.
Desert_Power
Footballguy
Such a frustrating market right now
